Skin Cancer Serum
Serum from IRB-consented donors with clinically confirmed skin cancer, processed and frozen within 24 hours. Supports work on established melanoma serum markers including LDH and S100B, soluble checkpoint proteins, immune-related adverse event signatures and tumour-associated antibody panels. Stratifiable by tumour type, stage, BRAF status and treatment.
Skin Cancer Serum for Tumour Immunology and Biomarker Research
Our Skin Cancer Human Serum is sourced from IRB-consented donors clinically diagnosed with skin cancer, with each sample processed and frozen within 24 hours of collection. Skin cancer is a neoplastic disease spanning melanoma and the keratinocyte carcinomas — cutaneous squamous cell carcinoma and basal cell carcinoma — all driven principally by ultraviolet-induced DNA damage. Serum captures the soluble protein and antibody dimension of that tumour biology and of the host immune response to it.
Why Serum for Skin Cancer
Cutaneous malignancies are among the most immunogenic human cancers, a direct consequence of the high mutational burden UV exposure produces. Serum sits at the intersection of tumour burden and immune response, and clotting removes fibrinogen and much of the coagulation cascade, giving a cleaner background for protein immunoassay and serology than plasma does.
- LDH is an established prognostic marker in advanced melanoma — elevated serum lactate dehydrogenase carries independent prognostic weight in metastatic melanoma and is formally incorporated into staging of distant metastatic disease, making it a genuine anchor analyte rather than a speculative one.
- S100B has a long research and clinical history — serum S100B is widely studied in melanoma as a marker correlating with tumour burden and outcome, particularly in European practice.
- Checkpoint inhibitor response and toxicity — melanoma was the proving ground for immune checkpoint blockade. Serum supports research on soluble PD-L1, cytokine correlates of response, and the autoantibody and inflammatory signatures associated with immune-related adverse events.
- Systemic inflammatory prognostic markers — IL-6, CRP and albumin-based composite indices carry prognostic information in advanced cutaneous malignancy and are all measurable from a single serum aliquot.
- Tumour-associated autoantibodies — serum, not plasma, is the correct matrix for humoral response work, including antibody responses to melanoma-associated antigens.
- Complementary to plasma — for circulating tumour DNA work such as BRAF V600E detection, EDTA plasma is the appropriate matrix; use serum for proteins and antibodies and pair it with the plasma sibling for genomics.
Donor Stratification Available
- Tumour type: melanoma, cutaneous squamous cell carcinoma, or basal cell carcinoma
- Stage at collection: localised, regionally advanced, or metastatic where recorded
- Primary tumour characteristics such as Breslow thickness and ulceration for melanoma where recorded
- BRAF and other driver mutation status where reported in the clinical record
- Treatment status: treatment-naive, post-surgical, checkpoint inhibitor, or BRAF/MEK-targeted therapy
- Documented response status and history of immune-related adverse events where available
- Matched healthy controls available, age- and sex-matched on request
Product Features
- Collected from clinically confirmed skin cancer donors
- Processed and frozen within 24 hours of collection
- Custom aliquot volumes available; volumes reported per lot
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
De-identified Donor Data
- Diagnosis confirmation, including histologic subtype where available
- Age, sex assigned at birth, and race/ethnicity
- Donor-reported medical history, medications and comorbidities
- Stage, molecular status and treatment history where reported
Applications
- Biomarker discovery and validation for cutaneous malignancy prognosis and monitoring
- LDH and S100B assay development and evaluation
- Soluble immune checkpoint protein research
- Serum cytokine and multiplex protein profiling in immunotherapy cohorts
- Immune-related adverse event and autoantibody research
- Tumour-associated antigen serology and antibody panel development
- Systemic inflammation and prognostic index research
- Assay qualification and reference material for dermato-oncology programmes
Other Skin Cancer Specimen Types
- Skin Cancer Plasma — for ctDNA and cell-free nucleic acid work
- Skin Cancer Whole Blood
- Skin Cancer PBMC
- Skin Cancer Leukopak
- Melanoma Whole Blood
- Basal Cell Carcinoma Skin Punch Biopsy
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Skin cancer serum is available in standard and custom volumes. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements to ensure compatibility with your country’s regulations. To browse availability across all disease states, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.